Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bangpungtongseong-san
- Development stage
- Unknown
- Lead developer
- Korea Institute of Oriental Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bangpungtongseong-san (BTS) is a traditional polyherbal formula used in Korean and East Asian medicine for the treatment of obesity, metabolic syndrome, and inflammatory conditions. It is composed of 18 different herbal ingredients, including *Ephedra herba*, *Glycyrrhizae radix*, *Platycodi radix*, and *Rheum palmatum*. BTS is thought to exert its anti-obesity effects through a multi-targeted mechanism that includes the activation of adrenergic receptors to promote thermogenesis, the inhibition of enteric lipid absorption, and the modulation of the gut microbiota, specifically by increasing the abundance of beneficial bacteria such as *Akkermansia muciniphila*. Additionally, it demonstrates anti-inflammatory properties by suppressing pro-inflammatory cytokines like tumor necrosis factor (TNF) and interleukin-6 (IL-6). BTS is frequently studied in clinical trials in South Korea and Japan for its efficacy in reducing body mass index (BMI) and improving glucose metabolism.
- Brand names
- BofutsushosanNaishitoruRohto Z
- Other names
- Fangfeng Tongsheng SanBofu-tsusho-sanBangpungtongseong-hwan
02
Targets
IL-6 (Interleukin 6)ADRB3 (β3)
Beyond the preview
Go deeper on bangpungtongseong-san.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bangpungtongseong-san.